Dimopoulos, M. A., Leleu, X. P., Beksac, M., Pour, L., Hajek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosińska, J., Špička, I., Vorobyev, V. I., Zamagni, E., Goldschmidt, H., Martin, T. G., Orlowski, R., Klippel, Z. K., Khan, U., Macé, S., Velde, H. V. D., Facon, T. (2025). Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7517